Key Highlights

● BRO closed at $62.88 on 9 October 2026, and the $75.63 consensus target implies upside of about 20.3%.

● The consensus draws on 20 analysts, with targets from $55 to $90.

● Market data shows five Buy, 14 Hold and one Sell rating, a Hold consensus.

● Oppenheimer initiated at Outperform with a $73 target on 7 October, while Mizuho cut to $78 from $83 and Barclays to $71 from $76.

Brown & Brown, Inc. (NYSE:BRO) is a US insurance broker, and its shares have attracted a flurry of analyst attention in the past week. The stock closed at $62.88 on Friday 9 October 2026.

What Is the Latest Analyst Price Target?

The consensus 12-month price target for Brown & Brown is $75.63, drawn from 20 analysts. Individual targets range from a low of $55.00 to a high of $90.00. Measured against the $62.88 close on 9 October 2026, the consensus target suggests potential upside of around 20.3%.

What Are Wall Street Analysts Saying?

Market data records 5 Buy ratings, 14 Hold ratings and 1 Sell rating, giving a consensus rating of Hold. Recent broker actions, as listed by market data, have leaned towards lower targets. On 7 October 2026 Oppenheimer initiated coverage with an Outperform rating and a $73.00 target, while Mizuho cut its target from $83.00 to $78.00 (Outperform) and Barclays lowered its target from $76.00 to $71.00 (Equal Weight).

On 6 October 2026 Morgan Stanley reduced its target from $60.00 to $55.00 with an Underweight rating, which is the lowest on the page. In a contrasting move, JPMorgan raised its target from $80.00 to $83.00 on 1 October 2026 while keeping a Neutral rating. Truist was listed with a $90.00 target on 29 July 2026, the highest figure shown.

What Could Help the Stock Reach the Price Target?

The gap between the share price and the average target is substantial, and several factors could narrow it. The consensus target suggests analysts see room for the shares to recover if earnings delivery improves. Steady organic growth in insurance brokerage, successful integration of acquisitions and firmer pricing in the insurance market have historically supported companies in this sector. Results that beat expectations, or evidence that recent target reductions were overly cautious, could also help sentiment.

What Could Prevent the Stock Reaching the Target?

The latest quarter, as summarised by market data, showed earnings per share of $1.07 against a consensus estimate of $1.08, and revenue of $1.65 billion against an estimate of $1.71 billion. With most analysts rated at Hold and several recently trimming their targets, the average may continue to drift lower. Softer insurance pricing, slower organic growth or acquisition integration difficulties could weigh on results. Because the consensus sits well above the current price, any further disappointment could widen that gap rather than close it.

What Should Investors Watch Next?

Items to watch include the next quarterly earnings report. Further target revisions from the brokers named above, any new initiations following Oppenheimer's, and commentary on organic growth, margins and acquisition activity will be useful signals. Changes in the consensus figure over the coming weeks will also indicate whether sentiment is stabilising.

Brown & Brown's Hold-Heavy Panel Leaves a Wide Gap Between Price and Average Target

Brown & Brown closed at $62.88 on 9 October 2026, with the $75.63 consensus target about 20.3% higher, and the range runs from Morgan Stanley's Underweight-rated $55 to Truist's $90. Most analysts are at Hold, with 14 of 20 ratings, and several have recently trimmed targets, including Mizuho and Barclays, even as Oppenheimer initiated at Outperform and JPMorgan raised to $83. Latest-quarter earnings per share of $1.07 against $1.08 and revenue of $1.65 billion against $1.71 billion mean that further disappointment could widen the gap between price and average target rather than close it.